Mira Kyivska

What's behind Hims & Hers Health's latest stock pullback?

What's behind Hims & Hers Health's latest stock pullback?
Hims & hers slides 3.99% today

Hims & Hers Health Inc (HIMS) dropped 3.99% after broad selling momentum continued to pressure the stock, even as the company introduced its new Peptides+ product line amid an expansion in compounded peptide and longevity treatments. The move is reinforced by HIMS trading below its 20-day, 50-day, and 200-day moving averages, highlighting persistent bearish momentum and a prevailing downward trend.

HIMS price prediction
24H -0.12%
$16.14
48H -0.93%
$16.01
7D -5.57%
$15.26
1M -40.66%
$9.59
3M -55.38%
$7.21
6M -73.51%
$4.28
12M -60.83%
$6.33
Current price: $16.16 -0.8950 5.25%
Real-time Data 14:40
Daily range 16.08 Arrow from to Icon 17.28
Weekly range 17.02 Arrow from to Icon 20.14
Loading...

Highlights

  • Hims & Hers Health introduced Peptides+, adding five new peptide and longevity treatments compounded in U.S. pharmacies after regulatory changes.
  • Revenue increased 49% year over year to $890.4 million and subscribers rose 13% to 2.8 million, but the company posted an operating loss after a prior-year profit.
  • Shares of Hims & Hers Health last traded at $16.38 under broad selling pressure, with technical indicators confirming downside momentum and an expected five-day range of $14.82 to $17.94.

Peptides+ rollout and subscriber growth met by renewed losses, insider sale

Hims & Hers Health launched Peptides+, a new offering introducing five U.S.-compounded peptide and longevity treatments, following recent regulatory changes that eased restrictions on such compounds. Products are prepared in licensed pharmacies under state guidelines, with further expansion planned to include additional peptides. The company reported a 49% year-over-year revenue increase to $890.4 million and a 13% rise in subscribers to 2.8 million, but returned to operating losses after a prior-year profit. The CFO also sold 3,518 shares on November 17, 2026, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees persistent bearish momentum controlling Hims & Hers Health, with the stock trading below all major moving averages. He notes that seller dominance is confirmed by multiple technical signals, including negative MACD, ADX, and persistent price pressure that brought shares close to session lows. Kharitonov points out that oversold oscillators may hint at near-term selling exhaustion, but he warns there is no evidence of a firm bottom. He is especially wary of the recent return to operating losses and pressure from insider selling. "Contagious selling pressure and technical weakness suggest investors should stay defensive and avoid premature bullish bets," says Kharitonov.
Viktoras Karapetjanc, expert at Traders Union, highlights the ongoing product expansion at Hims & Hers Health and strong year-over-year revenue growth. He views the launch of the Peptides+ line as evidence of management’s focus on innovation and regulatory adaptability. Karapetjanc believes robust subscriber growth and entry into longevity treatments provide solid long-term prospects despite short-term price action. "I see further opportunities for growth as regulatory changes create new markets and the company strengthens its leadership in digital health," says Karapetjanc.
Sholanke Dele, market strategist, believes broad selling momentum and a recent spike in volatility are eroding market confidence in Hims & Hers Health. He is critical of the weak investor sentiment driven by the stock's inability to rebound after new product announcements. Dele cautions that persistent operating losses and insider selling could further undermine support near $14.82. "Unless sentiment shifts quickly, HIMS may continue facing steep pressure from skeptical investors," says Dele.
Hims & Hers Health Inc. asset chart
Hims & Hers Health Inc. price dynamics. Source: TradingView.

Bearish technical trend confirmed as multiple oversold signals emerge

Hims & Hers Health is trading below the 20-day, 50-day, and 200-day moving averages at $24.13, $27.01, and $26.55, respectively, which signals broad pressure from sellers and a loss of short-, medium-, and long-term momentum. Immediate resistance is at $17.02 and support at $14.82, with additional overhead levels enforcing the dominant bearish trend. Momentum remains negative, confirmed by the MACD and ADX, while intraday volatility stands at 6.93%. RSI, Stochastic RSI, and CCI are all in oversold zones, suggesting potential selling exhaustion but not a confirmed bottom. BBP and the Awesome Oscillator also align with continued seller dominance, as intraday action brought the price near session lows after an early upside gap faded.

Earlier, analysts noted that Hims & Hers Health was experiencing sustained bearish momentum despite ongoing product portfolio expansion. The latest price action confirms continued technical weakness, with further downside risk if key support at $14.82 fails to hold in the days ahead.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.